Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Official Title

Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group

Summary:

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).

Trial Description

Primary Outcome:

  • Recurrence-free survival (RFS)
Secondary Outcome:
  • Distant metastasis-free survival (DMFS)
  • Overall survival (OS)
  • Safety - Incidence, nature, severity and seriousness of treatment emergent adverse events (TEAEs)
  • Safety -Incidence, nature and severity of cutaneous malignancies by dermatological examination
  • Safety -Incidence of Serious adverse events (SAEs)
  • Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in physical examination
  • Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in vital signs
  • Safety and tolerability : Incidence of TEAEs related to notable changes in clinical safety laboratory parameters from baseline.
  • Safety and tolerability -Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of 12-lead electrocardiograms (ECGs)
  • Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of echocardiogram or multigated acquisition (ECHO/MUGA) scans.
  • Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in ophtalmic examination
  • Safety and tolerability-Treatment emergent adverse events (TEAEs) leading to dose interruption, reduction and discontinuation.
  • Performance status using the Eastern Co-operative Oncology Group (ECOG) performance status scale.
  • Patient-reported health-related (HRQoL)-European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) .
  • Patient-reported health-related (HRQoL)_European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30)
  • Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)_Cmin
  • Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)-Cmax
  • Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)_AUC
  • Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-Cmin
  • Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-Cmax
  • Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-AUC

This is a randomized triple-blind placebo-controlled international multicenter phase III superiority clinical trial.

Participants with completely resected cutaneous melanoma and documented BRAF V600E/K status by central assay will be randomized 1 to 1 to receive either treatment with encorafenib and binimetinib or their two placebos for 12 months. Patients will be stratified according to the stage of the disease according to AJCC version 8 between:

  • stage IIB (i.e., pT3b or pT4a)
  • stage IIC (i.e., pT4b).

The long-term evaluation of all endpoints (including information about the occurrence of new treatment-related adverse events, if any) will take place 10 years from the randomization of the last patient.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society

Bookmark & Share